A carregar...

A phase 1 study of the pharmacokinetics of nucleoside analog trifluridine and thymidine phosphorylase inhibitor tipiracil (components of TAS-102) vs trifluridine alone

Background Trifluridine, a thymidine-based chemotherapeutic, has limited bioavailability after clinical administration as it is rapidly degraded via thymidine phosphorylase. An oral combination tablet combines trifluridine with a potent thymidine phosphorylase inhibitor, tipiracil hydrochloride. Thi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Invest New Drugs
Main Authors: Cleary, James M., Rosen, Lee S., Yoshida, Kenichiro, Rasco, Drew, Shapiro, Geoffrey I., Sun, Weijing
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2017
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5352756/
https://ncbi.nlm.nih.gov/pubmed/28111727
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-016-0409-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!